MARKET

GMAB

GMAB

Genmab
NASDAQ
35.36
+0.04
+0.11%
After Hours: 35.40 +0.04 +0.11% 19:30 09/28 EDT
OPEN
34.76
PREV CLOSE
35.32
HIGH
35.70
LOW
34.63
VOLUME
2.79M
TURNOVER
--
52 WEEK HIGH
35.70
52 WEEK LOW
23.62
MARKET CAP
21.71B
P/E (TTM)
27.86
1D
5D
1M
3M
1Y
5Y
1D
Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4
NASDAQ · 2d ago
Bank of America Securities Sticks to Their Buy Rating for Genmab A/S (0MGB)
TipRanks · 3d ago
Genmab Grants New Employee Restricted Stock Units and Warrants
TipRanks · 4d ago
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Barchart · 4d ago
Top 20 Nasdaq-100 names powering the NDX’s 2026 record run
Seeking Alpha · 6d ago
Weekly Report: what happened at GMAB last week (0914-0918)?
Weekly Report · 09/21 09:11
Analysts Are Bullish on These Healthcare Stocks: Genmab (GMAB), Medicus Pharma Ltd (MDCX)
TipRanks · 09/14 11:30
Genmab Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 09/14 10:25
More
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Webull offers Genmab A/S - ADR stock information, including NASDAQ: GMAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GMAB stock methods without spending real money on the virtual paper trading platform.